Detecting cancer early with advanced flow cytometry

bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths.

Diagnostics

CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.

Therapeutics

Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.

Early Detection of Cancer and Targeted Treatment Saves Lives

CyPath® Lung Flow Cytometry Test for Lung Cancer

Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Lung Flow Cytometry Test for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test.

0%
Sensitivity ⃰
0%

Specificity ⃰ 

0%
NPV ⃰

⃰ In individuals at high risk for lung cancer with nodules less than 20 mm, (n=132)

Precision Pathology Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ

Early Detection of Lung Cancer Saves Lives

Meeting a Critical Need to Detect Lung Cancer Early

Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Lung Flow Cytometry Test for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test.

At-Home Sample Collection

With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung.

▶  Video Demonstration

Flow Cytometry

Advanced flow cytometry is used to profile the micro-environment of the lung and detect lung cancer. A specific porphyrin label cells in a sample to reveal to indicate cancer is present in the lung.

▶  Video Demonstration

Automated Data Analysis

Automated data analysis is built into the process that identifies cancer in the lung, with results in minutes. Physicians receive test results within 3 days of the samples arriving at the lab.

Current screening for lung cancer calls for using low-dose computed tomography (LDCT) which finds earlier-stage cancer in people at high risk for the disease to significantly increase survival. Screening is an important tool to find early lung cancer and increase survival, but LDCT has a low positive predictive value that can lead to unnecessary invasive procedures.

CyPath® Lung is ordered by physicians for patients who they suspect have lung cancer. CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures, and lower patient anxiety and medical costs.

Research & Development Efforts

Scientific Publications & Abstracts

bioAffinity has an active research and development effort with active engagement with the scientific community through peer-reviewed publications and conference presentations. We are actively working to expand our core porphyrin platform technology to create targeted diagnostics and therapeutics in the fight against cancer.